Compass Pathways (MEX:CMPSN) Other Current Receivables: MXN264.44 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:CMPSN Compass Pathways PLC MEX:CMPSN
12 GF Score
Price MXN242.00
! 1 Warning Sign
View Full Analysis

What is Compass Pathways Other Current Receivables?

Compass Pathways MEX:CMPSN 12 Other Current Receivables is MXN264.44 Mil as of Jun. 2026. GuruFocus rates MEX:CMPSN with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Compass Pathways's Other Current Receivables for the quarter that ended in Jun. 2026 was MXN264.44 Mil.

Compass Pathways's quarterly Other Current Receivables declined from Dec. 2025 (MXN277.05 Mil) to Mar. 2026 (MXN272.84 Mil) but then stayed the same from Mar. 2026 (MXN272.84 Mil) to Jun. 2026 (MXN264.44 Mil).

Compass Pathways's annual Other Current Receivables declined from Dec. 2023 (MXN491.05 Mil) to Dec. 2024 (MXN431.96 Mil) and declined from Dec. 2024 (MXN431.96 Mil) to Dec. 2025 (MXN277.05 Mil).

Compass Pathways Other Current Receivables Related Terms

Compass Pathways Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Compass Pathways's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Compass Pathways Other Current Receivables Chart

Compass Pathways Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial 230.09 304.61 491.05 431.96 277.05

Compass Pathways Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 702.86 739.40 277.05 272.84 264.44
MEX:CMPSN
12GF Score
Compass Pathways PLC MEX:CMPSN
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Compass Pathways Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of MXN264.44 Mil mean?
Compass Pathways (MEX:CMPSN) has a Other Current Receivables of MXN264.44 Mil as of Jun. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Compass Pathways and its competitors.
Is Compass Pathways' Other Current Receivables too high?
Compass Pathways' current Other Current Receivables is MXN264.44 Mil. Overall, Compass Pathways has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Compass Pathways' Other Current Receivables compare to ARDT and HCSG?
Compass Pathways' Other Current Receivables of MXN264.44 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Healthcare Providers & Services company?
A good Other Current Receivables depends on the Healthcare Providers & Services industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Compass Pathways and its competitors. Compass Pathways's current Other Current Receivables is MXN264.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Pathways stock overvalued right now?
Compass Pathways (MEX:CMPSN) has a current Other Current Receivables of MXN264.44 Mil. The current Other Current Receivables is MXN264.44 Mil. Compass Pathways' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Compass Pathways (MEX:CMPSN), the current Other Current Receivables is MXN264.44 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Compass Pathways Business Description

Other Exchanges CMPS:USA5Y6:Germany
Address 33 Broadwick Street, London, GBR, W1F 0DQ
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
12GF Score

Get the complete analysis for MEX:CMPSN

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN242.00
Price